These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

584 related articles for article (PubMed ID: 17549046)

  • 1. In silico pharmacology for drug discovery: applications to targets and beyond.
    Ekins S; Mestres J; Testa B
    Br J Pharmacol; 2007 Sep; 152(1):21-37. PubMed ID: 17549046
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling.
    Ekins S; Mestres J; Testa B
    Br J Pharmacol; 2007 Sep; 152(1):9-20. PubMed ID: 17549047
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemogenomic approaches to drug discovery: similar receptors bind similar ligands.
    Klabunde T
    Br J Pharmacol; 2007 Sep; 152(1):5-7. PubMed ID: 17533415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From drug target to leads--sketching a physicochemical pathway for lead molecule design in silico.
    Shaikh SA; Jain T; Sandhu G; Latha N; Jayaram B
    Curr Pharm Des; 2007; 13(34):3454-70. PubMed ID: 18220783
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemogenomic approaches to rational drug design.
    Rognan D
    Br J Pharmacol; 2007 Sep; 152(1):38-52. PubMed ID: 17533416
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systems Pharmacology in Small Molecular Drug Discovery.
    Zhou W; Wang Y; Lu A; Zhang G
    Int J Mol Sci; 2016 Feb; 17(2):246. PubMed ID: 26901192
    [TBL] [Abstract][Full Text] [Related]  

  • 7. TargetHunter: an in silico target identification tool for predicting therapeutic potential of small organic molecules based on chemogenomic database.
    Wang L; Ma C; Wipf P; Liu H; Su W; Xie XQ
    AAPS J; 2013 Apr; 15(2):395-406. PubMed ID: 23292636
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The importance of discerning shape in molecular pharmacology.
    Kortagere S; Krasowski MD; Ekins S
    Trends Pharmacol Sci; 2009 Mar; 30(3):138-47. PubMed ID: 19187977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of in silico approaches to predicting drug--drug interactions.
    Ekins S; Wrighton SA
    J Pharmacol Toxicol Methods; 2001; 45(1):65-9. PubMed ID: 11489666
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Free resources to assist structure-based virtual ligand screening experiments.
    Villoutreix BO; Renault N; Lagorce D; Sperandio O; Montes M; Miteva MA
    Curr Protein Pept Sci; 2007 Aug; 8(4):381-411. PubMed ID: 17696871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The topology of drug-target interaction networks: implicit dependence on drug properties and target families.
    Mestres J; Gregori-Puigjané E; Valverde S; Solé RV
    Mol Biosyst; 2009 Sep; 5(9):1051-7. PubMed ID: 19668871
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computer-aided drug design and virtual screening of targeted combinatorial libraries of mixed-ligand transition metal complexes of 2-butanone thiosemicarbazone.
    Khan T; Ahmad R; Azad I; Raza S; Joshi S; Khan AR
    Comput Biol Chem; 2018 Aug; 75():178-195. PubMed ID: 29883916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ligand-based approaches to in silico pharmacology.
    Vidal D; Garcia-Serna R; Mestres J
    Methods Mol Biol; 2011; 672():489-502. PubMed ID: 20838981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chemogenomics knowledge-based strategies in drug discovery.
    Jacoby E; Schuffenhauer A; Floersheim P
    Drug News Perspect; 2003 Mar; 16(2):93-102. PubMed ID: 12792670
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of ADME characteristics in drug discovery and their in silico evaluation: in silico screening of chemicals for their metabolic stability.
    Gombar VK; Silver IS; Zhao Z
    Curr Top Med Chem; 2003; 3(11):1205-25. PubMed ID: 12769701
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The QSAR Paradigm in Fragment-Based Drug Discovery: From the Virtual Generation of Target Inhibitors to Multi-Scale Modeling.
    Kleandrova VV; Speck-Planche A
    Mini Rev Med Chem; 2020; 20(14):1357-1374. PubMed ID: 32013845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Importance of molecular computer modeling in anticancer drug development.
    Geromichalos GD
    J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An ontology for pharmaceutical ligands and its application for in silico screening and library design.
    Schuffenhauer A; Zimmermann J; Stoop R; van der Vyver JJ; Lecchini S; Jacoby E
    J Chem Inf Comput Sci; 2002; 42(4):947-55. PubMed ID: 12132896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ligand-based approach to in silico pharmacology: nuclear receptor profiling.
    Mestres J; Martín-Couce L; Gregori-Puigjané E; Cases M; Boyer S
    J Chem Inf Model; 2006; 46(6):2725-36. PubMed ID: 17125212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using quantitative systems pharmacology for novel drug discovery.
    Pérez-Nueno VI
    Expert Opin Drug Discov; 2015 Dec; 10(12):1315-31. PubMed ID: 26328768
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.